Welcome to our dedicated page for Pelthos Therapeutics news (Ticker: PTHS), a resource for investors and traders seeking the latest updates and insights on Pelthos Therapeutics stock.
Pelthos Therapeutics Inc. (PTHS) generates news primarily around its commercial dermatology portfolio and corporate development activities. As a biopharmaceutical company focused on therapeutic products for unmet patient needs, much of its coverage relates to the launch and market uptake of ZELSUVMI (berdazimer) topical gel, 10.3%, an FDA-approved at-home treatment for molluscum contagiosum in adults and pediatric patients one year of age and older.
Investors following Pelthos can expect regular updates on product commercialization milestones, including prescription trends, prescriber adoption, and payer access for ZELSUVMI. Company press releases have highlighted commercial agreements with pharmacy benefit managers and group purchasing organizations that expand formulary coverage and patient access, as well as educational initiatives such as the Moms Against Molluscum movement aimed at caregivers managing molluscum contagiosum.
News flow also covers portfolio expansion. Pelthos has announced acquisitions of Xepi (ozenoxacin) Cream, 1%, an FDA-approved topical treatment for impetigo, and Xeglyze (abametapir), an FDA-approved topical treatment for head lice infestation. These transactions, together with planned product relaunch timelines, feature prominently in company communications as Pelthos builds a broader cutaneous infectious disease franchise.
On the corporate and financial side, Pelthos issues releases on quarterly financial results, private financings, and credit facilities. Examples include senior secured convertible notes with investors including Ligand Pharmaceuticals and a senior secured term loan facility with Horizon Technology Finance Corporation, both described as supporting commercialization of ZELSUVMI and the integration of additional products. Governance and investor relations updates, such as board appointments and participation in healthcare and investor conferences, also appear in the company’s news stream.
For readers and investors, the Pelthos news page offers a consolidated view of these developments, providing context on how the company is executing its strategy in molluscum contagiosum, impetigo, and head lice, and how financing and partnerships are aligned with its commercial objectives.
Pelthos Therapeutics (NYSE: PTHS) acquired U.S. commercialization rights to Xepi (ozenoxacin) Cream, 1% and closed an $18 million private convertible notes financing on Nov 7, 2025. Pelthos paid $3.0M to Biofrontera and $1.2M to Ferrer upfront, with additional sales‑based milestones and royalties payable. Xepi is FDA‑approved for impetigo in patients two months and older; Pelthos plans a re‑launch in late 2026. The Notes bear 8.5% interest, mature Nov 6, 2027, and convert at an initial price of $34.442. Proceeds will fund the Xepi relaunch, commercial acceleration of ZELSUVMI, and working capital.
Pelthos Therapeutics (NYSE American: PTHS) will report third quarter 2025 financial results and host a conference call on Thursday, November 13, 2025 at 8:00 a.m. Eastern Time.
The company said a press release with financial results will be issued prior to the call. Management will discuss results for the quarter ended September 30, 2025, followed by a Q&A session. Dial-in details: toll-free 1-877-451-6152, international 1-201-389-0879, Conference ID 13756828. A live webcast will be available at the provided webcast URL.
Pelthos Therapeutics (NYSE: PTHS) on Oct 9, 2025 launched the Moms Against Molluscum movement and MomsAgainstMolluscum.com to unite families affected by molluscum contagiosum and share resources.
The company highlights its prescription topical ZELSUVMI (berdazimer) 10.3% gel, launched in July 2025 and described as a once-daily, at-home nitric oxide-releasing treatment. ZELSUVMI received a Novel Drug designation from the FDA in Jan 2024. The release cites disease burden: an estimated 16.7 million Americans affected and up to 6 million new U.S. incidents annually, mostly children.
Pelthos Therapeutics (NYSE American: PTHS) announced its participation in two upcoming investor conferences in September 2025. The company's CEO Scott Plesha and CFO Frank Knuettel II will represent Pelthos at the H.C. Wainwright 27th Annual Global Investment Conference in New York City and the Investor Summit Group Q3 Virtual Conference.
At the H.C. Wainwright conference, scheduled for September 8-10, 2025, management will deliver a presentation on September 10 at 10:30 A.M. ET and will be available for one-on-one meetings. The virtual Investor Summit Group conference will take place on September 16-17, 2025. A webcast of the H.C. Wainwright presentation will be available on Pelthos' website with a 90-day replay period.
Pelthos Therapeutics (NYSE American: PTHS), a biopharmaceutical company, announced its participation in the upcoming Wells Fargo Healthcare Conference. CEO Scott Plesha and CFO Frank Knuettel will deliver a presentation on Wednesday, September 3rd, 2025 at 1:30 p.m. ET.
The presentation will be accessible via webcast on the Events and Presentations section of Pelthos' website, with replays available for 90 days following the event. Institutional investors interested in one-on-one meetings should contact their sales representatives.
Pelthos Therapeutics (NYSE American: PTHS) reported Q2 2025 financial results and significant business developments. The company completed a merger with Channel Therapeutics and secured a $50.1 million private placement financing led by Murchinson Ltd. on July 1, 2025.
Key highlights include the successful launch of ZELSUVMI™, the first FDA-approved at-home treatment for molluscum contagiosum, targeting a market of 16.7 million affected people with up to 6 million new cases annually in the US. The company has expanded its infrastructure, hiring 50 territory sales managers and growing to over 90 employees. The company's current market cap is approximately $55 million, with an implied value of $165 million post-conversion of Series A Preferred Stock.
Pelthos Therapeutics (NYSE American: PTHS) has launched ZELSUVMI™ (berdazimer) topical gel 10.3%, marking a significant milestone as the first and only FDA-approved at-home treatment for molluscum contagiosum. The novel nitric oxide-releasing gel, which received FDA Novel Drug designation in January 2024, is now commercially available through prescription.
In Phase 3 clinical trials involving 891 patients, ZELSUVMI demonstrated complete clearance in 33% of patients compared to 19.7% in the control group at week 12, with some patients showing results within two weeks. The treatment targets an estimated 16.7 million affected people in the United States, with up to 6 million new cases annually.
To support the launch, Pelthos has deployed 50 sales territory managers nationwide and implemented the ZelsuvmiGo patient support program to facilitate patient access and education.
Pelthos Therapeutics (NYSE:PTHS) has completed its merger with Channel Therapeutics and secured a $50.1 million private placement. The combined company will begin trading on the NYSE American exchange under the ticker PTHS on July 2, 2025.
The private placement, led by Murchinson Ltd., includes the cancellation of $18.8 million in bridge capital. Pelthos will focus on launching ZELSUVMI™, an FDA-designated novel drug for molluscum contagiosum infections, which affects approximately 16.7 million people in the United States. The medication is the first prescription treatment that can be administered at home.
The company will also evaluate NaV 1.7 development programs for various pain treatments. Scott Plesha will serve as CEO, while former Channel Therapeutics CEO Frank Knuettel II becomes CFO of the combined entity.